Cadence Pharmaceuticals is reporting mixed results from two Phase III trials of Acetavance, an intravenous version of acetaminophen. One trial missed its primary endpoint of reducing pain intensity levels over 48 hours. That particular study did, however, meet several secondary endpoints. A second trial of Acetavance met its primary endpoint, demonstrating a statistically significant reduction of fever over six hours compared to a placebo. Investors didn't take kindly to the mixed results, sending Cadence's shares down--plunging 28 percent in pre-market trading.
- see this release from Cadence